Quote of the Day

"Generic inflation will force payers to rethink their formulary strategies. The priciest generic drugs are still less expensive than brands. However, these products have exploded in price due to shortages, which leads to generic-to-brand substitution. Some older brand-name drugs are experiencing a sales boost from the combination of high generic prices and shortages.... Generic price increases are inflaming the already-tense relationships between pharmacies and PBMs. Pharmacies believe that PBMs are not reimbursing at current market rates. PBMs should be concerned, because pharmacy owners are successfully lobbying for new restrictions on PBM pricing flexibility and MAC transparency state laws."



— Adam Fein, Ph.D., president of Pembroke Consulting, Inc., in an interview with AIS’s Drug Benefit News following his firm’s recent analysis of July NADAC data posted on his Drug Channels blog.